{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T10:31:42Z","timestamp":1773916302326,"version":"3.50.1"},"reference-count":60,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2011,4,1]],"date-time":"2011-04-01T00:00:00Z","timestamp":1301616000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,4,1]],"date-time":"2011-04-01T00:00:00Z","timestamp":1301616000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,8]],"date-time":"2022-06-08T00:00:00Z","timestamp":1654646400000},"content-version":"vor","delay-in-days":4086,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","exphem.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental Hematology"],"published-print":{"date-parts":[[2011,4]]},"DOI":"10.1016\/j.exphem.2011.01.005","type":"journal-article","created":{"date-parts":[[2011,1,27]],"date-time":"2011-01-27T04:24:12Z","timestamp":1296102252000},"page":"457-472.e3","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":43,"title":["Targeting of active mTOR inhibits primary leukemia T cells and synergizes with cytotoxic drugs and signaling inhibitors"],"prefix":"10.1016","volume":"39","author":[{"given":"Ana","family":"Batista","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jo\u00e3o T.","family":"Barata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elke","family":"Raderschall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen E.","family":"Sallan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nadia","family":"Carlesso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lee M.","family":"Nadler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angelo A.","family":"Cardoso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.exphem.2011.01.005_bib1","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1056\/NEJMra021902","article-title":"Rules for making human tumor cells","volume":"347","author":"Hahn","year":"2002","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.exphem.2011.01.005_bib2","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0092-8674(00)81683-9","article-title":"The hallmarks of cancer","volume":"100","author":"Hanahan","year":"2000","journal-title":"Cell"},{"key":"10.1016\/j.exphem.2011.01.005_bib3","first-page":"3689","article-title":"The Pezcoller lecture: cancer cell cycles revisited","volume":"60","author":"Sherr","year":"2000","journal-title":"Cancer Res"},{"key":"10.1016\/j.exphem.2011.01.005_bib4","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1126\/science.1073096","article-title":"Cancer. Addiction to oncogenes\u2014the Achilles heal of cancer","volume":"297","author":"Weinstein","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.exphem.2011.01.005_bib5","doi-asserted-by":"crossref","first-page":"3151","DOI":"10.1038\/sj.onc.1207542","article-title":"Target of rapamycin (TOR): an integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression","volume":"23","author":"Fingar","year":"2004","journal-title":"Oncogene"},{"key":"10.1016\/j.exphem.2011.01.005_bib6","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S0092-8674(00)00117-3","article-title":"TOR, a central controller of cell growth","volume":"103","author":"Schmelzle","year":"2000","journal-title":"Cell"},{"key":"10.1016\/j.exphem.2011.01.005_bib7","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1073\/pnas.95.4.1432","article-title":"RAFT1 phosphorylation of the translational regulators p70 S6 kinase and 4E-BP1","volume":"95","author":"Burnett","year":"1998","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.exphem.2011.01.005_bib8","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1146\/annurev.biochem.68.1.913","article-title":"eIF4 initiation factors: effectors of mRNA recruitment to ribosomes and regulators of translation","volume":"68","author":"Gingras","year":"1999","journal-title":"Annu Rev Biochem"},{"key":"10.1016\/j.exphem.2011.01.005_bib9","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1101\/gad.351605","article-title":"Ribosomal protein S6 phosphorylation is a determinant of cell size and glucose homeostasis","volume":"19","author":"Ruvinsky","year":"2005","journal-title":"Genes Dev"},{"key":"10.1016\/j.exphem.2011.01.005_bib10","first-page":"3504","article-title":"A direct linkage between the phosphoinositide 3-kinase-AKT signaling pathway and the mammalian target of rapamycin in mitogen-stimulated and transformed cells","volume":"60","author":"Sekulic","year":"2000","journal-title":"Cancer Res"},{"key":"10.1016\/j.exphem.2011.01.005_bib11","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/S1471-4914(01)02161-X","article-title":"PI 3-kinase, mTOR, protein synthesis and cancer","volume":"7","author":"Vogt","year":"2001","journal-title":"Trends Mol Med"},{"key":"10.1016\/j.exphem.2011.01.005_bib12","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1038\/ncb839","article-title":"TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling","volume":"4","author":"Inoki","year":"2002","journal-title":"Nat Cell Biol"},{"key":"10.1016\/j.exphem.2011.01.005_bib13","doi-asserted-by":"crossref","first-page":"7455","DOI":"10.1038\/sj.onc.1209085","article-title":"Perturbations of the AKT signaling pathway in human cancer","volume":"24","author":"Altomare","year":"2005","journal-title":"Oncogene"},{"key":"10.1016\/j.exphem.2011.01.005_bib14","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1146\/annurev.immunol.14.1.483","article-title":"Immunopharmacology of rapamycin","volume":"14","author":"Abraham","year":"1996","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.exphem.2011.01.005_bib15","first-page":"1527","article-title":"Antitumor activity of the rapamycin\u00a0analog CCI-779 in human primitive neuroectodermal tumor\/medulloblastoma models as single agent and in combination chemotherapy","volume":"61","author":"Geoerger","year":"2001","journal-title":"Cancer Res"},{"key":"10.1016\/j.exphem.2011.01.005_bib16","doi-asserted-by":"crossref","first-page":"7031","DOI":"10.1158\/1078-0432.CCR-04-0361","article-title":"Targeting mammalian target\u00a0of rapamycin synergistically enhances chemotherapy-induced cytotoxicity in breast cancer cells","volume":"10","author":"Mondesire","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.exphem.2011.01.005_bib17","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1158\/0008-5472.CAN-05-2447","article-title":"Mechanism by which mammalian target of\u00a0rapamycin inhibitors sensitize multiple myeloma cells to dexamethasone-induced apoptosis","volume":"66","author":"Yan","year":"2006","journal-title":"Cancer Res"},{"key":"10.1016\/j.exphem.2011.01.005_bib18","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.ccr.2006.09.006","article-title":"Gene expression-based chemical genomics identifies rapamycin as a modulator of MCL1 and glucocorticoid resistance","volume":"10","author":"Wei","year":"2006","journal-title":"Cancer Cell"},{"key":"10.1016\/j.exphem.2011.01.005_bib19","first-page":"6141","article-title":"Inhibitors of mTOR reverse doxorubicin resistance conferred by PTEN status in prostate cancer cells","volume":"62","author":"Grunwald","year":"2002","journal-title":"Cancer Res"},{"key":"10.1016\/j.exphem.2011.01.005_bib20","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1182\/blood-2009-09-220020","article-title":"Targeting the translational machinery as a novel treatment strategy for hematologic malignancies","volume":"115","author":"Hagner","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2011.01.005_bib21","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1038\/leu.2010.170","article-title":"Perspectives on inhibiting mTOR as a future treatment strategy for hematological malignancies","volume":"24","author":"Chapuis","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2011.01.005_bib22","doi-asserted-by":"crossref","first-page":"2661","DOI":"10.1182\/blood.V86.7.2661.2661","article-title":"Vascular cell adhesion molecule 1-positive reticular cells express interleukin-7 and stem cell factor in the bone marrow","volume":"86","author":"Funk","year":"1995","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2011.01.005_bib23","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1002\/jlb.48.3.205","article-title":"Constitutive expression of interleukin-7 mRNA and production of IL-7 by a cloned murine thymic stromal cell line","volume":"48","author":"Sakata","year":"1990","journal-title":"J Leukoc Biol"},{"key":"10.1016\/j.exphem.2011.01.005_bib24","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1080\/10428190400027852","article-title":"Interleukin-7 in T-cell acute lymphoblastic leukemia: an extrinsic factor supporting leukemogenesis?","volume":"46","author":"Barata","year":"2005","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.exphem.2011.01.005_bib25","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1084\/jem.20040789","article-title":"Activation of PI3K is indispensable for interleukin 7-mediated viability, proliferation, glucose use, and growth of T cell acute lymphoblastic leukemia cells","volume":"200","author":"Barata","year":"2004","journal-title":"J Exp Med"},{"key":"10.1016\/j.exphem.2011.01.005_bib26","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1126\/science.1102160","article-title":"Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia","volume":"306","author":"Weng","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.exphem.2011.01.005_bib27","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1182\/blood-2006-08-039883","article-title":"Notch signals positively regulate activity of the mTOR pathway in T-cell acute lymphoblastic leukemia","volume":"110","author":"Chan","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2011.01.005_bib28","doi-asserted-by":"crossref","first-page":"6172","DOI":"10.1182\/blood-2008-02-136762","article-title":"Targeting the Notch1 and mTOR pathways in a mouse T-ALL model","volume":"113","author":"Cullion","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2011.01.005_bib29","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1182\/blood-2002-12-3861","article-title":"IL-7-dependent human leukemia T-cell line as a valuable tool for drug discovery in T-ALL","volume":"103","author":"Barata","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2011.01.005_bib30","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/0065-2571(84)90007-4","article-title":"Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors","volume":"22","author":"Chou","year":"1984","journal-title":"Adv Enzyme Regul"},{"key":"10.1016\/j.exphem.2011.01.005_bib31","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1101\/gad.1212704","article-title":"Upstream and downstream of mTOR","volume":"18","author":"Hay","year":"2004","journal-title":"Genes Dev"},{"key":"10.1016\/j.exphem.2011.01.005_bib32","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.cell.2004.06.028","article-title":"Single cell profiling of potentiated phospho-protein networks in cancer cells","volume":"118","author":"Irish","year":"2004","journal-title":"Cell"},{"key":"10.1016\/j.exphem.2011.01.005_bib33","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.molcel.2006.03.029","article-title":"Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt\/PKB","volume":"22","author":"Sarbassov","year":"2006","journal-title":"Mol Cell"},{"key":"10.1016\/j.exphem.2011.01.005_bib34","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1182\/blood.V98.5.1524","article-title":"Interleukin-7 promotes survival and cell cycle progression of T-cell acute lymphoblastic leukemia cells by down-regulating the cyclin-dependent kinase inhibitor p27(kip1)","volume":"98","author":"Barata","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2011.01.005_bib35","doi-asserted-by":"crossref","first-page":"6436","DOI":"10.1038\/sj.onc.1209886","article-title":"mTOR and cancer therapy","volume":"25","author":"Easton","year":"2006","journal-title":"Oncogene"},{"key":"10.1016\/j.exphem.2011.01.005_bib36","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/nrc839","article-title":"The phosphatidylinositol 3-kinase AKT pathway in human cancer","volume":"2","author":"Vivanco","year":"2002","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.exphem.2011.01.005_bib37","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.ydbio.2004.06.008","article-title":"PTENless means more","volume":"273","author":"Stiles","year":"2004","journal-title":"Dev Biol"},{"key":"10.1016\/j.exphem.2011.01.005_bib38","doi-asserted-by":"crossref","first-page":"2954","DOI":"10.1200\/JCO.2004.02.141","article-title":"The biology and clinical relevance of the PTEN tumor suppressor pathway","volume":"22","author":"Sansal","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.exphem.2011.01.005_bib39","doi-asserted-by":"crossref","first-page":"10314","DOI":"10.1073\/pnas.171076798","article-title":"Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP\/mTOR","volume":"98","author":"Neshat","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.exphem.2011.01.005_bib40","doi-asserted-by":"crossref","first-page":"3762","DOI":"10.1172\/JCI34616","article-title":"PTEN posttranslational inactivation and hyperactivation of the PI3K\/Akt pathway sustain primary T\u00a0cell leukemia viability","volume":"118","author":"Silva","year":"2008","journal-title":"J Clin Invest"},{"key":"10.1016\/j.exphem.2011.01.005_bib41","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1182\/blood-2005-06-2208","article-title":"Proangiogenic stimulation of bone marrow endothelium engages mTOR and is inhibited by simultaneous blockade of mTOR and NF-kappaB","volume":"107","author":"Costa","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2011.01.005_bib42","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/j.exphem.2006.01.013","article-title":"Leukemia-stimulated bone marrow endothelium promotes leukemia cell survival","volume":"34","author":"Veiga","year":"2006","journal-title":"Exp Hematol"},{"key":"10.1016\/j.exphem.2011.01.005_bib43","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1038\/nature03703","article-title":"In vivo imaging of specialized bone marrow endothelial microdomains for tumour engraftment","volume":"435","author":"Sipkins","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.exphem.2011.01.005_bib44","doi-asserted-by":"crossref","first-page":"7579","DOI":"10.1158\/0008-5472.CAN-04-0641","article-title":"CC chemokine ligand 25 enhances resistance to apoptosis in CD4+ T cells from patients with T-cell lineage acute and chronic lymphocytic leukemia by means of livin activation","volume":"64","author":"Qiuping","year":"2004","journal-title":"Cancer Res"},{"key":"10.1016\/j.exphem.2011.01.005_bib45","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1182\/blood.V98.4.925","article-title":"Blocking of c-FLIP(L)\u2014independent cycloheximide-induced apoptosis or Fas-mediated apoptosis by the CC chemokine receptor 9\/TECK interaction","volume":"98","author":"Youn","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2011.01.005_bib46","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1158\/0008-5472.CAN-05-2925","article-title":"mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt","volume":"66","author":"O\u2019Reilly","year":"2006","journal-title":"Cancer Res"},{"key":"10.1016\/j.exphem.2011.01.005_bib47","doi-asserted-by":"crossref","first-page":"3130","DOI":"10.1073\/pnas.0400063101","article-title":"Combination of rapamycin and protein tyrosine kinase (PTK) inhibitors for the treatment of leukemias caused by oncogenic PTKs","volume":"101","author":"Mohi","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.exphem.2011.01.005_bib48","doi-asserted-by":"crossref","first-page":"7428","DOI":"10.1128\/MCB.22.21.7428-7438.2002","article-title":"The\u00a0rapamycin-binding domain governs substrate selectivity by the\u00a0mammalian target of rapamycin","volume":"22","author":"McMahon","year":"2002","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.exphem.2011.01.005_bib49","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1182\/blood-2005-03-0929","article-title":"Rapamycin stimulates apoptosis of childhood acute lymphoblastic leukemia cells","volume":"106","author":"Avellino","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2011.01.005_bib50","doi-asserted-by":"crossref","first-page":"15113","DOI":"10.1073\/pnas.2436348100","article-title":"Rapamycin is active against B-precursor leukemia in vitro and in vivo, an effect that is modulated by IL-7-mediated signaling","volume":"100","author":"Brown","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.exphem.2011.01.005_bib51","doi-asserted-by":"crossref","first-page":"2831","DOI":"10.1016\/j.molimm.2007.01.021","article-title":"Differential modulation of mitogen driven proliferation and homeostasis driven proliferation of T cells by rapamycin, Ly294002 and chlorophyllin","volume":"44","author":"Sharma","year":"2007","journal-title":"Mol Immunol"},{"key":"10.1016\/j.exphem.2011.01.005_bib52","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1182\/blood.V91.2.561","article-title":"The upregulation of p27Kip1 by rapamycin results in G1 arrest in exponentially growing T-cell lines","volume":"91","author":"Kawamata","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2011.01.005_bib53","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1038\/nm761","article-title":"PKB\/Akt phosphorylates p27, impairs nuclear import of p27 and opposes p27-mediated G1 arrest","volume":"8","author":"Liang","year":"2002","journal-title":"Nat Med"},{"key":"10.1016\/j.exphem.2011.01.005_bib54","doi-asserted-by":"crossref","first-page":"615","DOI":"10.2174\/156652405774641115","article-title":"Targeting the kinase activity of the BCR-ABL fusion protein in patients with chronic myeloid leukemia","volume":"5","author":"Giles","year":"2005","journal-title":"Curr Mol Med"},{"key":"10.1016\/j.exphem.2011.01.005_bib55","doi-asserted-by":"crossref","first-page":"4181","DOI":"10.1182\/blood-2004-03-1153","article-title":"In vivo antitumor effects of the mTOR inhibitor CCI-779 against human multiple myeloma cells in a xenograft model","volume":"104","author":"Frost","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2011.01.005_bib56","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1182\/blood-2004-06-2494","article-title":"Antileukemic activity of\u00a0rapamycin in acute myeloid leukemia","volume":"105","author":"Recher","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2011.01.005_bib57","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1182\/blood-2005-05-1935","article-title":"The mTOR inhibitor CCI-779 induces apoptosis and inhibits growth in preclinical models of primary adult human ALL","volume":"107","author":"Teachey","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2011.01.005_bib58","doi-asserted-by":"crossref","first-page":"4188","DOI":"10.1182\/blood-2004-06-2281","article-title":"Combination of the mTOR inhibitor rapamycin and CC-5013 has synergistic activity in multiple myeloma","volume":"104","author":"Raje","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2011.01.005_bib59","doi-asserted-by":"crossref","first-page":"4261","DOI":"10.1182\/blood-2004-11-4468","article-title":"mTOR regulates cell survival after etoposide treatment in primary AML cells","volume":"106","author":"Xu","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2011.01.005_bib60","doi-asserted-by":"crossref","first-page":"3520","DOI":"10.1158\/0008-5472.CAN-08-4884","article-title":"Dual inhibition of class IA phosphatidylinositol 3-kinase and mammalian target of rapamycin as a new therapeutic option for T-cell acute lymphoblastic leukemia","volume":"69","author":"Chiarini","year":"2009","journal-title":"Cancer Res"}],"container-title":["Experimental Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301472X11000130?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301472X11000130?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T08:28:44Z","timestamp":1759566524000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0301472X11000130"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,4]]},"references-count":60,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2011,4]]}},"alternative-id":["S0301472X11000130"],"URL":"https:\/\/doi.org\/10.1016\/j.exphem.2011.01.005","relation":{},"ISSN":["0301-472X"],"issn-type":[{"value":"0301-472X","type":"print"}],"subject":[],"published":{"date-parts":[[2011,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting of active mTOR inhibits primary leukemia T cells and synergizes with cytotoxic drugs and signaling inhibitors","name":"articletitle","label":"Article Title"},{"value":"Experimental Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.exphem.2011.01.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 ISEH - Society for Hematology and Stem Cells. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}